(Q42440190)

31 October 2017

title

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function (English)

1 reference

31 October 2017

2

B Ahrén

1 reference

31 October 2017

M Alba

1

1 reference

31 October 2017

S E Inzucchi

3

1 reference

31 October 2017

Y Guan

4

1 reference

31 October 2017

M Mallick

5

1 reference

31 October 2017

L Xu

6

1 reference

31 October 2017

E A O'Neill

7

1 reference

31 October 2017

D E Williams-Herman

8

1 reference

31 October 2017

K D Kaufman

9

1 reference

31 October 2017

B J Goldstein

10

1 reference

31 October 2017

publication date

19 July 2013

1 reference

Diabetes, Obesity and Metabolism

31 October 2017

published in

1 reference

31 October 2017

volume

15

1 reference

31 October 2017

issue

12

1 reference

31 October 2017

page(s)

1101-1110

1 reference

Type 2 diabetes--treat early, treat intensively

31 October 2017

cites work

1 reference

Overcoming obstacles in risk factor management in type 2 diabetes mellitus

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes

21 January 2018

1 reference

Pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

21 January 2018

1 reference

An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.

21 January 2018

1 reference

Insulin-dependent actions of pioglitazone in newly diagnosed, drug naïve patients with type 2 diabetes

21 January 2018

1 reference

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

21 January 2018

1 reference

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

21 January 2018

1 reference

Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

21 January 2018

1 reference

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

Oral glucose tolerance test minimal model indexes of beta-cell function and insulin sensitivity

21 January 2018

1 reference

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

21 January 2018

1 reference

Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests

21 January 2018

1 reference

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

Comparative analysis of two rates

21 January 2018

1 reference

Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

21 January 2018

1 reference

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

21 January 2018

1 reference

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes

21 January 2018

1 reference

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures

21 January 2018

1 reference

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12145

1 reference

31 October 2017

1 reference